Table 5.

Outgrowth of human AML cells in NOD/SCID mice

% human AML cells
Phenotype of the original AML sample
FAB
FIt3 status
% CXCR-4+
% CD34+
% CD34+CXCR-4+
% of CD34+expressing CXCR-4
1   0.5   M5   ITD   6.2   95.2   5.9   6.2  
2   0.9   M2   wt   27.0   86.8   11.3   13.0  
3   0.9   M2   wt   13.0   75.6   8.0   10.6  
4   2.5   M5   wt   5.9   1.7   0.2   12.0  
5   3.1   M4   wt   11.7   46.3   9.1   19.7  
6   4.6   M5   wt   51.2   76.0   28.7   37.7  
7   8.3   M1   wt   18.2   92.3   16.3   16.3  
8   9.2   M5   wt   33.4   82.9   28.8   34.8  
9   9.7   M2   wt   34.2   95.2   25.6   26.8  
10   11.8   M5   wt   39.3   11.4   9.6   84.5  
11   13.4   M5   wt   24.0   1.2   0.9   75.0  
12   14.4   M4   wt   51.2   52.6   26.9   51.2  
13   15.1   M4   ITD   98.5   1.0   0.3   26.8  
14   26.6   M4   wt   16.8   5.7   2.5   43.9  
15   30.1   M2   ITD   90.1   0.2   0.2   100  
16   37.6   M0   wt   4.6   1.6   0.6   40.5  
17   38.5   M1   wt   23.0   0.7   0.5   70.4  
18   38.5   M0   wt   92.6   96.3   83.7   86.9  
19   48.6   M2   ITD   56.2   1.5   1.0   66.7  
20   81.7   M2   ITD   59.3   26.5   8.0   30.3  
21
 		 97.8
 		 M5
 		 ITD
 		 73.2
 		 0.3
 		 0.2
 		 72.0
 
% human AML cells
Phenotype of the original AML sample
FAB
FIt3 status
% CXCR-4+
% CD34+
% CD34+CXCR-4+
% of CD34+expressing CXCR-4
1   0.5   M5   ITD   6.2   95.2   5.9   6.2  
2   0.9   M2   wt   27.0   86.8   11.3   13.0  
3   0.9   M2   wt   13.0   75.6   8.0   10.6  
4   2.5   M5   wt   5.9   1.7   0.2   12.0  
5   3.1   M4   wt   11.7   46.3   9.1   19.7  
6   4.6   M5   wt   51.2   76.0   28.7   37.7  
7   8.3   M1   wt   18.2   92.3   16.3   16.3  
8   9.2   M5   wt   33.4   82.9   28.8   34.8  
9   9.7   M2   wt   34.2   95.2   25.6   26.8  
10   11.8   M5   wt   39.3   11.4   9.6   84.5  
11   13.4   M5   wt   24.0   1.2   0.9   75.0  
12   14.4   M4   wt   51.2   52.6   26.9   51.2  
13   15.1   M4   ITD   98.5   1.0   0.3   26.8  
14   26.6   M4   wt   16.8   5.7   2.5   43.9  
15   30.1   M2   ITD   90.1   0.2   0.2   100  
16   37.6   M0   wt   4.6   1.6   0.6   40.5  
17   38.5   M1   wt   23.0   0.7   0.5   70.4  
18   38.5   M0   wt   92.6   96.3   83.7   86.9  
19   48.6   M2   ITD   56.2   1.5   1.0   66.7  
20   81.7   M2   ITD   59.3   26.5   8.0   30.3  
21
 		 97.8
 		 M5
 		 ITD
 		 73.2
 		 0.3
 		 0.2
 		 72.0
 

There were 15 Fit3 wild-type and 6 FIt3/ITD samples analyzed in the NOD/SCID mouse model. Per group, 3 to 5 mice were injected with 3 × 107 AML cells. After 6 weeks, the mice were killed and bone marrow cells harvested. The percentage of human AML cells in the bone marrow was analyzed by flow cytometry and compared with the CXCR-4 and CD34 expression patterns of the samples before grafting.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal